New Study Shows Ozempic and Semaglutide May Lower Risk of Severe Liver Diseases

A nationwide study in Sweden suggests that GLP1 agonists like Ozempic could lower the risk of cirrhosis and liver cancer in individuals with type 2 diabetes and chronic liver disease. This new finding provides a potential life-saving benefit of these medications, offering a new treatment option for preventing severe liver diseases.